Compare WEN & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEN | IMCR |
|---|---|---|
| Founded | 1969 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2000 | 2016 |
| Metric | WEN | IMCR |
|---|---|---|
| Price | $6.87 | $28.59 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 22 | 10 |
| Target Price | $8.84 | ★ $66.33 |
| AVG Volume (30 Days) | ★ 8.3M | 432.7K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 8.28% | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | 0.12 | ★ 0.25 |
| Revenue | ★ $2,176,891,000.00 | $249,428,000.00 |
| Revenue This Year | $2.26 | $14.57 |
| Revenue Next Year | $0.94 | $8.21 |
| P/E Ratio | ★ $57.83 | $114.16 |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $6.37 | $27.56 |
| 52 Week High | $12.51 | $40.71 |
| Indicator | WEN | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 44.84 | 49.22 |
| Support Level | $6.62 | $27.66 |
| Resistance Level | $7.28 | $31.56 |
| Average True Range (ATR) | 0.31 | 1.21 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 25.56 | 51.86 |
The Wendy's Co is engaged in operating, developing, and franchising a system of distinctive quick-service restaurants serving high-quality food. The company operates through Wendy's U.S., Wendy's International, and Global Real Estate & Development. Wendy's U.S. and Wendy's International include the operation and franchising of restaurants and derive revenues from sales at company-operated restaurants, as well as royalties, franchise fees, and advertising fund collections from franchised restaurants. Global Real Estate & Development includes real estate activities for owned and leased sites that are leased or subleased to franchisees and includes the company's share of income from its Canadian restaurant real estate joint venture.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.